ADIL Adial Pharmaceuticals

Adial Pharmaceuticals to Present at the 2023 Jefferies Global Healthcare Conference on June 9th

Adial Pharmaceuticals to Present at the 2023 Jefferies Global Healthcare Conference on June 9th

CHARLOTTESVILLE, Va., June 01, 2023 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, announced today that it will be presenting at the Jefferies 2023 Global Healthcare Conference being held June 7-9, 2023, at the Marriott Marquis in New York, NY.

Cary Claiborne, Chief Executive Officer of Adial Pharmaceuticals, is scheduled to present on Friday, June 9, 2023 at 12:15 p.m. Eastern Time. The presentation will be webcast live and available for replay at .

For questions, please email  or .

About Adial Pharmaceuticals, Inc.

Adial Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of therapies for the treatment and prevention of addiction and related disorders. The Company’s lead investigational new drug product, AD04, is a genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder (AUD) in heavy drinking patients and was recently investigated in the Company’s ONWARD™ pivotal Phase 3 clinical trial for the potential treatment of AUD in subjects with certain target genotypes (estimated to be approximately one-third of the AUD population) identified using the Company’s proprietary companion diagnostic genetic test. ONWARD showed promising results in reducing heavy drinking in heavy drinking patients, and no overt safety or tolerability concerns. AD04 is also believed to have the potential to treat other addictive disorders such as Opioid Use Disorder, gambling, and obesity. The Company is also developing adenosine analogs for the treatment of pain and other disorders. Additional information is available at

Contact:

Crescendo Communications, LLC

David Waldman / Alexandra Schilt

Tel: 212-671-1020

Email:



EN
01/06/2023

Underlying

ADILAdial Pharmaceuticals

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Adial Pharmaceuticals

 PRESS RELEASE
Free
ADIL Adial Pharmaceu...

Adial Pharmaceuticals Reports Second Quarter 2025 Financial Results an...

Adial Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update GLEN ALLEN, Va., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today provided a business update and reported its financial results for the second quarter of 2025. Cary Claiborne, CEO of Adial Pharmaceuticals, commented, “We believe we are at an inflection point in Adial’s journey. With the suc...

August 14, 2025 1 EN
 PRESS RELEASE
Free
ADIL Adial Pharmaceu...

Adial Pharmaceuticals Completes Successful EOP2 FDA Meeting

Adial Pharmaceuticals Completes Successful EOP2 FDA Meeting Meeting Completion Marks Major Step Toward Phase 3 AD04 Trial Launch Strategic Partnership Discussions Expected Following the Positive FDA Meeting GLEN ALLEN, Va., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced the completion of a successful End of Phase 2 meeting (EOP2M) with the Food and Drug Administration (FDA...

August 6, 2025 1 EN
 PRESS RELEASE
Free
ADIL Adial Pharmaceu...

Adial Pharmaceuticals Regains Compliance with Nasdaq Stockholders’ Equ...

Adial Pharmaceuticals Regains Compliance with Nasdaq Stockholders’ Equity Listing Requirement GLEN ALLEN, Va., July 16, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that it received notice from Nasdaq on July 14, 2025 that the Company has regained compliance with Nasdaq Listing Rule 5550(b)(1), which requires listed companies to maintain stockholders' equity of at least $2,500,000....

July 16, 2025 1 EN
 PRESS RELEASE
Free
ADIL Adial Pharmaceu...

Adial Pharmaceuticals Files PCT Patent Application to Protect Core Ass...

Adial Pharmaceuticals Files PCT Patent Application to Protect Core Assets and Extend IP Exclusivity on Core Technology to at least 2045 Application Update Based on Extensive Review of Data GLEN ALLEN, Va., July 09, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, announced the filing of an update to the provisional patent application for AD04 which was filed in July 2024, the Company’s lead investig...

July 9, 2025 1 EN
 PRESS RELEASE
Free
ADIL Adial Pharmaceu...

Adial Pharmaceuticals Secures U.S.-Based Manufacturing Through Agreeme...

Adial Pharmaceuticals Secures U.S.-Based Manufacturing Through Agreements with Cambrex and Thermo Fisher Scientific for Drug Substance and Drug Product Supply Scope of Agreement with Cambrex to Provide Ondansetron HCL Drug Substance Under FDA Approved Drug Master File Scope Of Agreement With Thermo Fisher to Provide Manufacturing Services Including Demonstration, Clinical, Registration And Validation Batches of AD04 for US Clinical Trials And NDA Submission GLEN ALLEN, Va., June 25, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinica...

June 25, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch